ERBB2 and breast cancer: It has also been reported that 1-10% of ER-positive tumours are heterogeneous and crossover with not only luminal A/B but also HER2-enriched and basal-like (14, 31–34), indicating a mixed distribution of molecular subtypes in HR-low/HER2-negative BC by IHC.